Journal
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE
Volume 84, Issue 2, Pages 12-20Publisher
AMER SOC TROP MED & HYGIENE
DOI: 10.4269/ajtmh.2011.09-0516
Keywords
-
Funding
- World Health Organization Initiative for Vaccine Research [LA35735G]
- National Institute of Allergy and Infectious Diseases (NIAID) [49486/TMRC]
- Colombian National Research Council, COLCIENCIAS [487-2003]
- Colombian Ministry for Social Protection [conv. 255-2004]
- Malaria Vaccine and Drug Development Center Foundation
- Brazilian Conselho Nacional de Desenvolvimento Cientifico e Tecnologico - CNPq
- National Institutes of Health (NIH) [NIH/NO1-AI-05403]
Ask authors/readers for more resources
We assessed the safety, tolerability, and immunogenicity of a mixture of three synthetic peptides derived from the Plasmodium vivax circumsporozoite protein formulated in Montanide ISA 720 or Montanide ISA 51. Forty healthy malaria-naive volunteers were allocated to five experimental groups (A-E): four groups (A-D) were immunized intramuscularly with 50 and 100 mu g/dose injections of a mixture of N, R, and C peptides formulated in the two different adjuvants at 0, 2, and 4 months and one group was administered placebo. Vaccines were immunogenic, safe, well tolerated, and no serious adverse events related to the vaccine occurred. Seroconversion occurred in >90% of the vaccines and antibodies recognized the sporozoite protein on immunofluorescent antibody test. Vaccines in Montanide ISA 51 showed a higher sporozoite protein recognition and interferon production. Results encourage further testing of the vaccine protective efficacy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available